Key takeaways
- Eli Lilly developed retatrutide. Its scientists described the molecule, then coded LY3437943, in a 2022 paper covering laboratory and mouse work and a phase 1 single-ascending-dose study.
- It is a 39-amino-acid peptide on a GIP-based sequence, with a fatty acid attached, that activates the GIP, GLP-1 and glucagon receptors.
- Retatrutide is its International Nonproprietary Name, in PubMed from 2023. PubMed records naming it or its code rose from 2 in 2022 to 111 in 2026 (our count, to 18 November).
- Phase 3 trials began in 2023, their papers appeared from June to November 2026, and Lilly plans a US filing in the first quarter of 2027.
- The regulator actions we found start in December 2024: FDA warning letters, MHRA seizures and TGA laboratory tests of products sold under the name.
01Retatrutide history at a glance
A dated record, from the idea to November 2026.
| Date | What happened |
|---|---|
| Dec 2014 | An international academic and industry group describes a single peptide acting at the GLP-1, GIP and glucagon receptors, tested in rodents (Nature Medicine). It is not retatrutide; a 2026 review cites it as the preclinical demonstration of the approach. |
| Dec 2019 – Dec 2020 | Lilly enrols 72 adults with type 2 diabetes at four US centres in a phase 1b trial of LY3437943 (NCT04143802). |
| 18 Aug 2022 | Lilly scientists publish LY3437943 in Cell Metabolism: laboratory work, studies in obese mice and a phase 1 single-ascending-dose study. |
| 27 Oct 2022 | The phase 1b trial appears in The Lancet. Its primary outcome was safety and tolerability. |
| 2023 | The name retatrutide appears in PubMed titles and abstracts; the earliest records we found that use it date from 2023. |
| 26 Jun 2023 | Two phase 2 trials appear online: in obesity (NEJM; 338 adults; 48 weeks) and in type 2 diabetes (The Lancet; 281 adults in the US). |
| May – Aug 2023 | Phase 3 begins: TRIUMPH-3 on 30 May, TRIUMPH-1 on 10 July, TRIUMPH-2 on 11 July and TRIUMPH-4 on 1 August (registry start dates). |
| Feb – Apr 2024 | Phase 3 trials in type 2 diabetes begin, among them TRANSCEND-T2D-1 (10 April). The heart and kidney outcomes trial, TRIUMPH-Outcomes, begins on 30 April. |
| 10 Dec 2024 | FDA warning letter: an online seller’s “Retatrutide” (or “Reta”) products, labelled “RESEARCH USE ONLY”, are among unapproved new drugs. |
| 15 Oct 2025 | The TRIUMPH design paper is published: four registrational phase 3 trials, more than 5,800 participants. |
| 24 Oct 2025 | MHRA reports seizing unlicensed retatrutide and tirzepatide pens at a site in Northampton; retatrutide “has not been approved for UK use”. |
| Dec 2025 – Jul 2026 | Lilly announces phase 3 topline results by press release, as dated in a 2026 review: TRIUMPH-4 (December 2025), TRIUMPH-1 (May 2026), TRIUMPH-2 and TRIUMPH-3 (July 2026). |
| 6 Jun 2026 | TRANSCEND-T2D-1 is published in The Lancet: 537 adults with type 2 diabetes, 40 weeks. |
| 24 Aug 2026 | FDA warning letters to four online sellers list retatrutide products, including as “GLP-3 RT” and “GLP-3R”, among unapproved new drugs. |
| 14 Sep 2026 | TGA: a product sold as retatrutide, tested after a report of a serious adverse effect, contained “undeclared semaglutide and no retatrutide”. |
| 29 Sep 2026 | TRIUMPH-1 (NEJM) and TRIUMPH-2 (The Lancet) are published. Lilly says it “plans to submit a Biologics License Application (BLA) in Q1 2027”. |
| 1 Oct 2026 | FDA’s GLP-1 page: retatrutide “cannot be used in compounding under federal law”. |
| 9 Oct 2026 | A JAMA news feature on retatrutide and zenagamtide: “neither therapy has been approved by any regulatory authority in the world”. |
| 15 Oct 2026 | MHRA: “Retatrutide has not been authorised for use in the UK.” |
| 21 Oct and 8 Nov 2026 | The sleep apnoea sub-studies, then TRIUMPH-4 and TRIUMPH-1-OA, are published in NEJM. |
| 5 Nov 2026 | TGA laboratory: tested products from one brand “contained less retatrutide than stated on the label, with significant variation between samples”. |
| 18 Nov 2026 | Not approved in any country. |
02Where did retatrutide come from?
Retatrutide was made at Eli Lilly. The paper that introduced it, under the code LY3437943, came from Lilly scientists: every author declared being an employee and stockholder of the company. Published online on 18 August 2022 in Cell Metabolism, it covered laboratory work on the three receptors, studies in obese mice and a phase 1 single-ascending-dose study in people.
The idea of one peptide acting on all three receptors is older. In a paper published online in December 2014, an international academic and industry group described “a rationally designed monomeric peptide triagonist” in rodents. A 2026 review in Pharmaceutics cites that work as the preclinical demonstration of the approach, and Lilly’s molecule as its translation into clinical development. The 2014 peptide was not retatrutide.
We found no published date for when Lilly first made the molecule. What it is today, in brief: what is retatrutide?
03What is retatrutide’s structure?
The 2026 Pharmaceutics review describes retatrutide as a 39-amino-acid peptide with a GIP-based sequence. Three of its building blocks are not among the standard amino acids that make up proteins: α-aminoisobutyric acid (Aib) at positions 2 and 20, and α-methyl-L-leucine at position 13. Its end (the C-terminus) is amidated, and a 20-carbon fatty diacid is attached to the lysine at position 17 through a linker, a change called lipidation.
Lilly calls it a triple hormone receptor agonist; the review calls it a unimolecular tri-agonist. Both mean one molecule that acts on the GIP, GLP-1 and glucagon receptors, not three drugs mixed in one vial. How a chain of amino acids becomes a molecule like this: how peptides work.
04How did retatrutide get its name?
LY3437943 is its Lilly development code, used in the 2022 papers. Retatrutide is its International Nonproprietary Name (INN), the generic name assigned through the World Health Organization; the EMBL-EBI database ChEBI lists it as an INN, with WHO as the source. The name appears in PubMed titles and abstracts from 2023, the year of the phase 2 papers. We did not find the WHO list that first proposed it, so we give no date for the name itself.
“GLP-3” is not a name the research uses for retatrutide: no PubMed title or abstract on retatrutide uses it (18 Nov 2026). Sellers use the label: FDA warning letters dated 24 August 2026 record products listed as “Retatrutide (GLP-3 RT)” and “GLP-3R”, sold alongside products listed as “Semaglutide (GLP-1 SEM)” and “Tirzepatide (GLP-2 TRZ)”.
05How did research on retatrutide develop?
From one company’s discovery paper in 2022 to a phase 3 programme in 2026. Lilly sponsored and funded every human trial on this page.
Phase 1, 2022. The discovery paper included a phase 1 single-ascending-dose study. A 12-week phase 1b trial followed in The Lancet in October 2022: 72 adults with type 2 diabetes, randomised against placebo and dulaglutide, an approved prescription GLP-1 medicine. Its primary outcome was safety and tolerability.
Phase 2, 2023. Two trials appeared online on 26 June 2023. One enrolled 338 adults with obesity, or overweight with a weight-related condition, for 48 weeks (NEJM). The other enrolled 281 adults with type 2 diabetes at 42 US centres, against placebo and dulaglutide (The Lancet).
Phase 3, from 2023. The TRIUMPH obesity trials began between May and August 2023, and phase 3 trials in type 2 diabetes followed in 2024. ClinicalTrials.gov lists 14 phase 3 studies of retatrutide, all sponsored by Lilly: 5 completed and 9 active or recruiting (18 Nov 2026). Lilly announced topline results by press release first; journal papers followed in 2026, from TRANSCEND-T2D-1 in June to the knee osteoarthritis trials in November. TRIUMPH-3 has no journal paper yet (PubMed, 18 Nov 2026). Trial by trial: the retatrutide guide.
Volume. Our count of PubMed records naming retatrutide or LY3437943 in the title or abstract: 2 in 2022, 16 in 2023, 39 in 2024, 51 in 2025 and 111 in 2026 to 18 November, 219 in all. PubMed tags 134 of them as reviews. We do not repeat efficacy figures for a drug that is approved nowhere; what the grades mean: evidence grades.
06How have regulators treated retatrutide?
It has never been approved. The regulator actions we found concern products sold outside the trials, and they start in December 2024.
United States. On 10 December 2024 FDA wrote to an online seller that its “Retatrutide” (or “Reta”) products, labelled “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY”, were among unapproved new drugs. Letters to four more sellers followed on 24 August 2026. FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says retatrutide and cagrilintide “cannot be used in compounding under federal law” and “are not components of FDA-approved drugs and have not been found safe and effective for any condition”.
United Kingdom. On 24 October 2025 the MHRA reported seizing unlicensed retatrutide and tirzepatide pens at a site in Northampton and wrote that retatrutide “has not been approved for UK use”. On 15 October 2026 it said: “Retatrutide has not been authorised for use in the UK.” More: are peptides legal in the UK?
Australia. On 14 September 2026 the TGA reported that a product sold as retatrutide, tested after a report of a serious adverse effect, contained “undeclared semaglutide and no retatrutide”. On 5 November 2026 its laboratory found that tested products from one brand “contained less retatrutide than stated on the label, with significant variation between samples”. Both advisories say retatrutide “has not been approved by the TGA or any comparable international regulator”. More: are peptides legal in Australia?
Commentary. A JAMA news feature of 9 October 2026 on retatrutide and a second pipeline drug, zenagamtide, noted that “neither therapy has been approved by any regulatory authority in the world”. Other documented cases of mislabelled products: contamination and mislabeling.
07What we don’t know about retatrutide’s history
- When the name retatrutide was proposed. We did not find the WHO list entry.
- When Lilly first made the molecule, and why it chose this one. We read the 2022 discovery paper’s abstract, not its full structure–activity work.
- When products sold under the name first appeared online. The regulator actions we found start in December 2024.
- TRIUMPH-3’s full results. The trial is completed, but we found no journal paper (PubMed, 18 Nov 2026).
- Whether, when and for what any regulator will approve it. Lilly plans a US filing in the first quarter of 2027.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.